The impact of the prognostic nutritional index in gastric cancer

e16002 Background: To investigate the impact of preoperative prognostic nutritional index (PNI) on the severity of radiotherapy and chemotherapy toxicity and survival prognosis in patients with gastric cancer through retrospective analysis and research in order to guide clinical nutritional support treatment for patients with gastric cancer. Methods: Through a retrospective cohort study，we analyzed the data of 191 patients with gastric cancer in the Department of Gastrointestinal Surgery of the Affiliated Hospital of Guizhou Medical University and Guizhou Cancer Hospital from January 2008 to December 2018. According to the cut-off value, the patients were divided into high PNI group (PNI≥47.7) and low PNI group (PNI < 47.7). We Compared the incidences of severe radiotherapy and chemotherapy toxicities and overall survival in high PNI group and low PNI group. and make Analysis of prognostic factors. Results: The low PNI group was more prone to severe radiochemotherapy hematological side effects than the high PNI group, and the postoperative survival time was shorter. Multivariate analysis showed that: TNM stage (P = 0.000) and PNI (P = 0.001) were Independent risk factors in predicting overall survival rate. Conclusions: The preoperative prognostic nutrition index is a useful factor for predicting the incidence of radiotherapy and chemotherapy toxicities in patients after gastric cancer surgery.It is one of the important factors affecting the prognosis of gastric cancer and helps to guide the nutritional support treatment of gastric cancer patients.

Download Full-text

Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer

Anticancer Research ◽

10.21873/anticanres.13901 ◽

2019 ◽

Vol 39 (12) ◽

pp. 6843-6849 ◽

Cited By ~ 1

Author(s):

TOSHIYUKI KOSUGA ◽

TOMOKI KONISHI ◽

TAKESHI KUBOTA ◽

KATSUTOSHI SHODA ◽

HIROTAKA KONISHI ◽

...

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Prognostic Nutritional Index ◽

Node Metastasis ◽

Nutritional Index

Download Full-text

The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset

Digestive Surgery ◽

10.1159/000497454 ◽

2019 ◽

Vol 37 (2) ◽

pp. 135-144 ◽

Cited By ~ 8

Author(s):

Masahiro Sasahara ◽

Mitsuro Kanda ◽

Seiji Ito ◽

Yoshinari Mochizuki ◽

Hitoshi Teramoto ◽

...

Keyword(s):

Gastric Cancer ◽

Area Under The Curve ◽

Prognostic Nutritional Index ◽

Stage Ii ◽

Long Term Outcomes ◽

Short Term ◽

Nutritional Index ◽

Appropriate Treatment ◽

Disease Free

Background/Aims: Identification of nutritional indicators to predict short-term and long-term outcomes is necessary to provide appropriate treatment to patients with gastric cancer. Methods: We designed an analysis of a multicenter dataset of patients with gastric cancer who underwent gastrectomy between 2010 and 2014. We enrolled 842 eligible patients who had stage II/III gastric cancer. The area under the curve (AUC) values were compared among prognostic nutritional index (PNI), calculated as 10 × albumin g/dL + 0.005 × total lymphocyte count/mm3, and its constituents, and the predictive value of preoperative PNI for postoperative short-term and long-term outcomes was evaluated. Results: Preoperative PNI exhibited higher AUC values (0.719) for 1-year survival than its constituents, and the optimal cutoff value was 47. The disease-free and overall survival of patients in the PNI-low group were significantly shorter compared with those in the PNI-high group. The prognostic difference between the PNI-high and PNI-low groups was significantly greater in the subgroup of patients who underwent total gastrectomy. Clinically relevant postoperative complications were more frequently observed in the PNI-low group. Conclusions: The preoperative PNI is a useful predictor reflecting the incidence of complications after gastrectomy and the prognosis of patients with stage II/III gastric cancer.

Download Full-text

The usefulness of Roux-en-Y reconstruction with aboral pouch following total gastrectomy for gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.4_suppl.209 ◽

2017 ◽

Vol 35 (4_suppl) ◽

pp. 209-209

Author(s):

Shirou Iwagami ◽

Sugihara Hidetaka ◽

Takao Mizumoto ◽

Tatsuo Kubota ◽

Nobutomo Miyanari ◽

...

Keyword(s):

Gastric Cancer ◽

Total Gastrectomy ◽

Prognostic Nutritional Index ◽

Short Term ◽

Common Procedure ◽

Term Outcome ◽

Nutritional Parameters ◽

Nutritional Index ◽

One Year ◽

Outcome Of Surgery

209 Background: Patients with gastric cancer that involves the upper part of the stomach should undergo total gastrectomy for their curative resection. Roux-en-Y reconstruction is the most common procedure followingtotal gastrectomy. However, this reconstruction causes them various postgastrectomy symptoms and problems of their nutritional status and QOL. Although the development of the new reconstruction to prevent these symptoms have being carried out, we have not generally established procedures. Methods: To compare the feasibility and the nutritional parameters of the patients with Roux-en-Y reconstruction with aboral pouch following total gastrectomy to the simple Roux-en-Y. From February 2011 to June 2014, sixty three patients with gastric cancer underwent total gastrectomy. We analyzed the short-term outcome of surgery and the nutritional parameters in two groups. Results: The aboral pouch was created as a side to side anastomosis approximately 50 cms distal to the esophagojejunostomy, 12 cm in length. Most nutritional parameters after surgery were similar in two groups. However, lymphocyte, serum albumin and prognostic nutritional index in aboral pouch group one year later were good tendency compared with simple Roux-en-Y group. Conclusions: Roux-en-Y reconstruction with aboral pouch might become one of the standard methods after total gastrectomy for gastric cancer.

Download Full-text

Postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for pStage III gastric cancer: A cohort study.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.358 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. 358-358

Author(s):

Nobuhiro Tsuchiya ◽

Chikara Kunisaki

Keyword(s):

Gastric Cancer ◽

Adjuvant Chemotherapy ◽

Adverse Effects ◽

Therapy Group ◽

Sensory Neuropathy ◽

Prognostic Nutritional Index ◽

Postoperative Adjuvant Chemotherapy ◽

Curative Gastrectomy ◽

Nutritional Index ◽

Peripheral Sensory

358 Background: Adjuvant chemotherapy following curative gastrectomy is recommended for patients with pStage II or III, except pT3 (ss), N0 gastric cancer in Japan. This study aimed to compare the efficacy of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX for pStageIII gastric cancer. Methods: Between January 2015 and December 2018, 51 patients with pStage III gastric cancer underwent curative gastrectomy. The combination therapy group received a combined SOX and XELOX regimen as follows: (1) SOX regimen: 130 mg/m2 of oxaliplatin on day 1 every 3 weeks combined with 40 mg/m2 of S-1 twice daily on days 1–14 every 3 weeks; (2) XELOX regimen: 130 mg/m2 of oxaliplatin on day 1 every 3 weeks combined with 1000 mg/m2 of capecitabine twice daily on days 1–14 every 3 weeks. We evaluated their hospital records retrospectively. The indication of SOX/XELOX regimens was based on PS and intent of patients. Results: The S-1 group comprised 28 cases (pStage III A/B/C: 12/8/8), while the SOX/XELOX group comprised 23 cases (pStage III A/B/C: 4/10/9). There was no difference in age, sex, comorbidity, prognostic nutritional index and stage between two groups. The 2-year DFS of the S-1 group and the SOX/XELOX group were 58.6% and 71.7%, respectively (p = 0.367). Subgroup analysis showed that the 2-year DFS of patients with pStage IIIC gastric cancer in the S-1 group was significantly lower than the SOX/XELOX group (S-1 vs. SOX/XELOX: 25.9% vs. 78.7%, p = 0.041). As concerns adverse effects (CTCAE ver 4.0), peripheral sensory neuropathy was significantly higher in the SOX/XELOX group than in the S-1 group (S-1: grade I/II 3.6%/0% vs. SOX/XELOX: grade I/II 21.7%/34.8%, p < 0.001), although the other adverse effects did not differ between the two groups. Conclusions: SOX/XELOX therapy may be more useful than S-1 therapy for more advanced tumors among pStage III gastric cancers.

Download Full-text